To be compliant with the Global Fund QA policy, PR should inform by writing the Global Fund Portfolio Manager (FPM) if PR intends to procure Ci or Cii pharmaceutical product(s). If the Global Fund Secretariat has no objection regarding this selection, quality control testing by Global Fund contracted laboratory is requested prior any shipment of the products to the country.

The procedure to procure Ci and Cii pharmaceutical products is as following:

If the Principal Recipient (PR) intends to buy pharmaceutical products under Option Ci and Cii, they must notify in written the FPM at the GF Secretariat. (notification form)

• The Global Fund reviews the compliance of the selected pharmaceutical products with the Global Fund QA Policy.
• If the Global Fund has no objections, the Global Fund will inform both the laboratory and the PR.
• Global Fund contracted laboratory (SGS) contacts the supplier to request the relevant documentation.
• Global Fund contracted laboratory (SGS) selects batches for testing and performs the required tests.
• The Global Fund takes the final decision on the basis of the laboratory report.
• The Global Fund, informs the PR and the supplier of the final test results and the Global Fund’s decision.

Pharmaceutical products purchased under Option C should be tested as soon as the purchase of such product is planned and before any shipments of batches stored at the manufacturing site (or at procurement agent facilities) are sent to the PR.

This process is applicable for procuring all Ci or Cii pharmaceutical by the PR or by procurement agent, including the UN procurement agents.

• Summary table of procurement procedures for Ci and Cii pharmaceutical products
  
  
• Frequently-Asked Questions (FAQs) about Quality-Control Testing of Pharmaceutical Products Used in the Prevention and Treatment of HIV/AIDS, Tuberculosis and Malaria